Evaluation of a novel nanocrystalline hydroxyapatite paste Ostim in comparison to Alpha-BSM - more bone ingrowth inside the implanted material with Ostim compared to Alpha BSM.
BACKGROUND
The purpose of this study was to evaluate the performance a newly developed nanocrystalline hydroxyapatite, OSTIM following functional implantation in femoral sites in thirty-eight sheep for 1, 2 or 3 months. Ostim 35 was compared to an established calcium phosphate, Alpha BSM.


METHODS
Biomechanical testing, micro-CT analysis, histological and histomorphological analyses were conducted to compare the treatments including evaluation of bone regeneration level, material degradation, implant biomechanical characteristics.


RESULTS
The micro-computed tomography (microCT) analysis and macroscopic observations showed that Ostim seemed to diffuse easily particularly when the defects were created in a cancellous bone area. Alpha BSM remained in the defect.The performance of Ostim was good in terms of mechanical properties that were similar to Alpha BSM and the histological analysis showed that the bone regeneration was better with Ostim than with Alpha BSM. The histomorphometric analysis confirmed the qualitative analysis and showed more bone ingrowth inside the implanted material with Ostim when compared to Alpha BSM at all time points.


CONCLUSIONS
The successful bone healing with osseous consolidation verifies the importance of the nanocrystalline hydroxyapatite in the treatment of metaphyseal osseous volume defects in the metaphyseal spongiosa.
Huber
Franz-Xaver
FX
Klinik für Unfallchirurgie, Orthopädie und Wiederherstellungschirurgie, Klinikum Ansbach, Escherichstrasse 1 91522 Ansbach, Germany. franz-xaver.huber@klinikum-ansbach.de
McArthur
Nicholas
N
Heimann
Lydia
L
Dingeldein
Elvira
E
Cavey
Héloïse
H
Palazzi
Xavier
X
Clermont
Gaëlle
G
Boutrand
Jean-Pierre
JP
D020341:Absorbable Implants / Q000639:trends*; D000818:Animals; D001843:Bone Cements / Q000494:pharmacology* / Q000627:therapeutic use; D001847:Bone Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D004195:Disease Models, Animal; D017886:Durapatite / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D053758:Nanoparticles / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D034561:Sheep, Domestic; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology; D055114:X-Ray Microtomography
D001843:Bone Cements; D017886:Durapatite